CMS Quit Test Of Pricey Cancer Treatment Amid Concerns Over Industry Role

July 12, 2018

Medicare and Medicaid administrators earlier this year quietly killed a plan to pay for a breakthrough, half-million-dollar cancer treatment based on how well it worked, scuttling one of the Trump’s administration’s first and most highly touted attempts to lower the cost of drugs. The payment deal for Swiss drug giant Novartis’ Kymriah therapy was suspended […]

CMS to Allow Smartphones to Connect With CGM for Medicare Beneficiaries

June 21, 2018

The ban on letting people in Medicare connect their continuous glucose monitor (CGM) to a smartphone drew ire from patients, advocates, and even the Government Accountability Office. People in Medicare who wanted a continuous glucose monitor (CGM) to manage their diabetes will now be allowed to link it with their smartphone, allowing users to share […]

Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)

June 18, 2018

LONDON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that ORKAMBI® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people with two copies of the F508del mutation, ages six and older, will be reimbursed in Sweden after concluding the three-party negotiations with TLV and the county councils. Reimbursement is effective […]

Azar backs protections for preexisting conditions, skirting administration’s legal stance

June 14, 2018

Health and Human Services Secretary Alex Azar told lawmakers Tuesday that he wants to preserve access to affordable insurance for Americans with preexisting medical conditions, but he declined to disclose his view of an administration move that could undercut such consumer protections. Calling it “a constitutional position . . . not a policy position,” Azar sidestepped grilling […]

Mictoryl® Pediatric (propiverine hydrochloride) now covered by several public drug plans to treat symptoms associated with overactive bladder

June 8, 2018

BLAINVILLE, QC, June 7, 2018 /CNW Telbec/ – Duchesnay, a specialty pharmaceutical company with a longstanding commitment to women’s health, announced today that Mictoryl® Pediatric (propiverine hydrochloride 5 mg) has been added to the public drug plans of Alberta, New Brunswick, Ontario (limited use), Quebec and the Non-Insured Health Benefits (NIHB) Program.   Mictoryl® Pediatric […]

Addition of Cosentyx® to drug plan in Ontario and across Canada expands access to treatment for psoriatic arthritis and ankylosing spondylitis

June 6, 2018

DORVAL, QC, June 6, 2018 /CNW/ – Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that Ontario will now reimburse Cosentyx® (secukinumab) under the province’s public drug program for eligible adults with active psoriatic arthritis (PsA) and eligible adults with ankylosing spondylitis (AS).   Both PsA and AS are inflammatory diseases. PsA affects the […]

TESARO Announces Addition of ZEJULA to Cancer Drugs Fund in UK

June 1, 2018

ZUG, Switzerland, June 01, 2018 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the National Institute for Health and Care Excellence (NICE) will make ZEJULA® (niraparib), the first PARP inhibitor shown to be effective in patients with a BRCA mutation as well as those without a BRCA mutation, available to women […]

WellCare to Buy Meridian State Health Plans for $2.5 Billion

May 31, 2018

WellCare Health Plans Inc. will buy two state insurance businesses and a pharmacy benefit manager from Meridian for $2.5 billion, bulking up the company’s Medicaid offerings in Michigan and Illinois.   The all-cash deal for Meridian Health Plan of Michigan Inc. and Meridian Health Plan of Illinois Inc. will give Tampa-based WellCare about 1.07 million […]

Myriad Announces Seven New Payer Coverage Decisions for Prolaris®

May 24, 2018

SALT LAKE CITY, May 23, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced seven new commercial coverage decisions for Prolaris®, the company’s market leading prognostic test for patients with prostate cancer. The payers include a top-25 commercial insurer in the United States and in aggregate the payers […]

Envision Pharma Group announces the successful implementation of iEnvision to connect and support Otsuka’s medical affairs activities

May 15, 2018

Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) has completed the first phase of implementation of the iEnvision medical affairs platform developed by Envision Technology Solutions, part of Envision Pharma Group. iEnvision is a web-based software platform specifically designed and developed to support multiple medical affairs-related programs of activity. Otsuka is deploying iEnvision to manage several […]

Express Scripts Picks Regeneron Over Amgen, Cuts Heart Drug Price

May 3, 2018

Regeneron Pharmaceuticals and partner Sanofi have cut an unusual deal with Express Scripts, the nation’s largest drug-buying middleman. The two drug makers will cut the price of their $14,000-a-year cholesterol-lowering therapy alirocumab (Praluent). In return, Express Scripts will quickly approve treatment requests. The deal also sidelines Amgen, whose rival heart drug evolocumab (Repatha) will no […]